BioNTech CEO sells 39,000 shares. BioNTech stock has a USD 126.00 average target

Published on 10/01/2026 at 12:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 59.51 percent to USD 105.60 million in the second quarter. BioNTech stock costs EUR 86.18 on October 1, 2026 versus EUR 86.75.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech (ISIN US09075V1026) was trading at EUR 86.18 at Lang & Schwarz on October 1, 2026 at 12:07 p.m. CEST, while a recent insider filing put management activity back on the agenda. According to MarketBeat on September 24, 2026, CEO Ugur Sahin sold 39,000 shares at an average price of USD 98.99 under a pre-arranged trading plan. The same report cited a Moderate Buy consensus and a USD 126.00 average analyst target.

Insider sale meets analyst support

The sale was part of a broader series of transactions disclosed during September, while Sahin retained 341,209 shares after the transaction, according to MarketBeat. The contrast is material for the market narrative: insider selling supplies a cautionary signal, but the analyst average target remains above the latest US reference quote of USD 98.30 from September 30, 2026.

Analyst views are not uniform. Markets Insider reported on September 21, 2026 that Morgan Stanley maintained a Buy rating with a USD 115.00 target, while the same page listed Berenberg raising its target from USD 132.00 to USD 140.00 on September 16, 2026. The different targets show why the USD 126.00 average is more informative than any single estimate.

Second-quarter loss raises the bar

BioNTech reported USD 105.60 million in revenue for the second quarter of 2026, down from USD 260.80 million in the second quarter of 2025, a decline of 59.51 percent. GAAP net loss widened to USD 820.80 million from USD 386.60 million, according to Markets Insider.

The operating figures place the analyst optimism against a demanding earnings backdrop. MarketBeat reported a second-quarter loss of USD 2.53 per share against a USD 2.40 consensus loss and revenue of USD 122.31 million against USD 180.18 million expected, highlighting differences between reported data sets and the importance of the company release for future updates.

Oncology data remains central

BioNTech and OncoC4 presented updated September 14, 2026 data for gotistobart in previously treated squamous non-small cell lung cancer. The data showed median overall survival of 18.50 months versus 10.00 months with docetaxel, according to GlobeNewswire Europe. The 8.50-month difference gives the oncology pipeline a measurable counterweight to the weak commercial quarter.

Stock trades below prior close

At Lang & Schwarz, BioNTech stock was trading at EUR 86.18 on October 1, 2026 at 12:07 p.m. CEST, down 0.66 percent versus the prior close of EUR 86.75. The Nasdaq-listed ADR had a USD 79.52 to USD 124.00 52-week range and a USD 24.7 billion market capitalization as of September 30, 2026. MarketScreener lists November 2, 2026 as the next earnings release date for third-quarter 2026.

The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.